Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster
Managing Director & CEO, Dr Nina Webster
Source: Dimerix
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Dimerix (DXB) receives approval from the US FDA to proceed with a phase three study of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS)
  • An Investigational New Drug (IND) application for the study, dubbed ACTION3, is now active, paving the way for patient recruitment across 75 sites in 12 different countries
  • The third-phase trial has two interim analysis points designed to capture evidence of proteinuria and kidney function during the study
  • Dimerix says it expects the first part of the study to be completed during the first half of 2023, once 72 patients have completed 35 weeks of treatment
  • DXB shares are trading grey at 13 cents each as of 1:28 pm AEST

Dimerix (DXB) has received approval from the US Food and Drug Administration (FDA) to proceed with a phase three study of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS).

An Investigational New Drug (IND) application for the clinical study, dubbed ACTION3, is now active, paving the way for patient recruitment across 75 sites in 12 different countries, with 19 of those clinical sites having been selected in the US.

“FDA approval of our IND for the Phase Three FSGS study is an important milestone, as it includes regulatory review of all manufacturing, nonclinical and clinical data that we have generated for the DMX-200 program to date,” Dimerix CEO and Managing Director Dr Nina Webster said.

The aim of the study is to generate sufficient evidence to support accelerated marketing approval for Dimerix’s product.

The single third-phase study in FSGS patients has two interim analysis points designed to capture evidence of proteinuria and kidney function (eGFR slope) during the study.

The first part of the study will conclude after the first interim analysis — once 72 patients have completed 35 weeks of treatment — and is expected to occur in the first half of 2023.

Under the second part of the study, patients will need to demonstrate a minimum of six weeks of stable dosing of an angiotensin receptor blocker prior to randomisation and dosing with DMX-200 or placebo.

DXB shares were trading grey at 13 cents each as of 1:28 pm AEST.

DXB by the numbers
More From The Market Online
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…